Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) Relative Strength Index (RSI) is 45.25, with weekly volatility at 12.96% and ATR at 0.18. The CATB stock’s 52-week price range has touched low of $1.25 and a $8.59 high. Intraday shares traded counted 1.29 million, which was -39.51% lower than its 30-day average trading volume of 926.75K. Its shares traded lower over the last trading session, losing -4.76% on 06/21/21. The shares fell to a low of $1.9221 before closing at $2.00. CATB’s previous close was $2.10 while the outstanding shares total 22.38M. The firm has a beta of 1.64.
Investors have identified the Biotechnology company Catabasis Pharmaceuticals Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $162.66 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Catabasis Pharmaceuticals Inc. (CATB) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 147.68 million total, with 4.41 million as their total liabilities.
CATB were able to record -8.74 million as free cash flow during the 08/12/2021 quarter of the year, this saw their quarterly net cash flow reduce by 121.99 million. In cash movements, the company had a total of -8.72 million as operating cash flow.
Potential earnings growth for Catabasis Pharmaceuticals Inc. (CATB)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/12/2021 quarter of the year, Catabasis Pharmaceuticals Inc. recorded a total of 170.09 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 95.27% coming in sequential stages and their sales for the 08/12/2021 quarter increasing by 94.72%.
Having a look at the company’s valuation, the company is expected to record -0.77 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on CATB sounds very interesting.
Is the stock of CATB attractive?
In the last 6 months, insiders have changed their ownership in shares of company stock by 0.11%.
